PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE) Burmester, G., Amital, H., Rubbert-Roth, A., van Hoogstraten, H., Gervitz, L., Thangavelu, K., St John, G., Genovese, M. C. BMJ PUBLISHING GROUP. 2019: 1138–39

View details for DOI 10.1136/annrheumdis-2019-eular.4646

View details for Web of Science ID 000472207103323